Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20539460 | 0.80 | CHRNB2 (0.40) | CHRNB2CHRNA4 | |
| SCHEMBL24687082 | 0.80 | NQO1 (0.54) | CHRNB2CHRNA4 | |
| SCHEMBL2329756 | 0.79 | CYP1A2 (0.47) | — | |
| SCHEMBL17400969 | 0.76 | NQO1 (0.61) | — | |
| SCHEMBL5173631 | 0.76 | CHRNB2 (0.43) | CHRNB2CHRNA4 | |
| SCHEMBL5172747 | 0.76 | CHRNB2 (0.43) | CHRNB2CHRNA4 | |
| SCHEMBL5173626 | 0.76 | CHRNB2 (0.43) | CHRNB2CHRNA4 | |
| SCHEMBL2884157 | 0.75 | — | — | |
| SCHEMBL16519363 | 0.74 | NQO1 (0.46) | — | |
| SCHEMBL2889797 | 0.74 | PPARD (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846700-B2 | Heteroaryl quinazoline derivatives | MSD K.K. (JP) | 2014-09-30 | — | — | US | disclosed |
| EP-2221301-B1 | HETEROARYLOXY QUINAZOLINE DERIVATIVE | MSD KK (JP) | 2014-06-04 | — | — | EP | disclosed |
| US-20140011801-A1 | HETEROARYL QUINAZOLINE DERIVATIVES | MSD K.K. (JP) | 2014-01-09 | — | — | US | disclosed |
| US-20120270856-A1 | HETEROARYLOXY QUINAZOLINE DERIVATIVES | IINO TOMOHARU (JP) | 2012-10-25 | — | — | US | disclosed |
| US-8232284-B2 | Heteroaryloxy quinazoline derivative | MSD K. K. (JP) | 2012-07-31 | — | — | US | disclosed |
| US-20100249146-A1 | HETEROARYLOXY QUINAZOLINE DERIVATIVE | MSD K.K. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2221301-A1 | HETEROARYLOXY QUINAZOLINE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249146-A1 | HETEROARYLOXY QUINAZOLINE DERIVATIVE | GCKR, GCK, KHK | CHRNB2 3474/4885CHRNA4 3076/4885 |
| US-20140011801-A1 | HETEROARYL QUINAZOLINE DERIVATIVES | GCK, GCKR, KHK | CHRNB2 3528/4885CHRNA4 2975/4885 |
| US-20120270856-A1 | HETEROARYLOXY QUINAZOLINE DERIVATIVES | GCK, GCKR, KHK | CHRNB2 3469/4885CHRNA4 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.